Connected Support
For patients facing the difficult diagnosis of pulmonary hypertension functional class III1
When FC declines, their world begins to narrow, which can mean losing the things that provide a sense of self and purpose2-6
Their career
and working lifestyle4
Their capacity
to contribute to everyday tasks4
Their role within
a relationship4
Their hobbies
and interests3
Their independence4
When they stand to lose so much, effective treatment for PH functional class III could make a difference3,7,8
Improving quality of life, extending survival compared to placebo, and offering a chance to stay connected with the things that give life value3,5,7-9
Connected Therapy
Helping patients stay active and improve exercise capacity7,9-11
Prostacyclin analogues are one of the most effective classes of treatment for PH, within which there are distinct administration methods available to patients12-14
Ventavis® (iloprost trometamol) is an inhaled prostacyclin analogue and can help patients with progressive PH with functional class III
Click the dots to explore changing FC in response to prostacyclin analogue initiation
A primary goal of therapy is to move down in FC, but patients can only benefit from prostacyclin analogues if they are prescribed11,12,23
It is evident that quality of life falls along with FC2
As functional limitations increase, the disease really starts to take control of every aspect
of a patient’s life3-6
Prostacyclin analogues can make a substantial difference by improving symptoms and increasing survival compared to placebo – especially when used early9,12
Ventavis improves the symptoms of the disease, quality of life and FC compared with placebo9,10
Indicated
to help patients in FC III improve symptoms
and functional capacity1
Recommended
by the ESC/ERS guidelines as initial
therapy for those in FC III11
Ventavis is indicated for the treatment of adult patients with primary PH, classified as NYHA FC III, to improve exercise capacity and symptoms1
Sign up for exclusive access to new resources
References
- Ventavis Summary of Product Characteristics. Return to content
- Guillevin L et al. Eur Respir Rev 2013; 22(130): 535-42. Return to content
- FDA. The Voice of the Patient: Pulmonary Arterial Hypertension.December 2014. Return to content
- Pulmonary Hypertension Association Europe. The impact of pulmonary arterial hypertension (PAH) on patients and carers. September 2012. Return to content
- Kukkonen M et al. Eur Clin Respir J 2016; 3: 26405. Return to content
- Zlupko M et al. Respir Med 2008; 102(10): 1431-8. Return to content
- Barst RJ et al. Chest 2013; 144(1): 160-8. Return to content
- Kingman M et al. BMJ Open 2014; 4(5): e004735. Return to content
- Olschewski H et al. Ann Intern Med 1996; 124(9): 820-4. Return to content
- Olschewski H et al. N Eng J Med 2002; 347(5): 322-9. Return to content
- Galiè N et al. Eur Heart H 2016; 37(1): 67-119. Return to content
- Goncalvesova E. Eur Cardiol 2012; 8(3): 204-8 Return to content
- Baker WL et al. Ann Pharmacother 2017; 51(6): 488-95. Return to content
- Del Pozo R et al. Expert Rev Respir Med 2017; 11(6): 491-503. Return to content
- Hardin et al. Drug Des Devel Ther 2016; 10: 3747–54. Return to content
- Gomberg-Maitland M, Olschewski H. Eur Respir J 2008; 31(4): 891-901. Return to content
- Hill NS et al. Respir Care 2015; 60(6): 794-805. Return to content
- Sitbon O et al. N Engl J Med 2015; 373(26): 2522-33. Return to content
- Olschewski H. Eur Respir Rev 2009; 18(111): 29–34. Return to content
- Gessler T et al. J Aerosol Med Pulm Drug Deliv 2008; 21(1): 1-12. Return to content
- Hackman AM, Lackner TE. Pharmacotherapy 2006; 26(1): 68-94. Return to content
- Highland KB et al. Chest 2003; 124(6): 2087-92. Return to content
- McLaughlin VV et al. J Am Coll Cardiol 2013; 62(25 Suppl): D73-81. Return to content
- Farber HW et al. J Heart Lung Transplant 2013; 32(11): 1114-22. Return to content
Abbreviations
ESC: European Society of Cardiology
ERS: European Respiratory Society
FC: functional class
NYHA: New York Heart Association
PH: pulmonary hypertension
Ventavis is indicated for the treatment of adult patients with primary PH, classified as NYHA FC III, to improve exercise capacity and symptoms1
